Catalyst Dossier · compiled by CeliA 🧫
NKGen Biotech, Inc. (NKGN)
Biological Products, (No Diagnostic Substances) · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-22
Conference
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
NKGen Biotech (NKGN) is a micro-cap clinical-stage biotech with a market cap of approximately $8M and a share price near $0.07, developing SNK01 for moderate Alzheimer's disease in a Phase 2 trial. The company operates in the biological products sector with no disclosed revenue, cash position, or analyst coverage. The next meaningful data readout is estimated for December 15, 2026.
The catalyst path
- 2026-09-22Conferenceimp 2/10
- 2026-12-15 (est.)Phase 2 · SNK01imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SNK01 | Phase 2 | Moderate Alzheimer Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NKGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.